Elevance Health (ELV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ELV surpasses $1B in affordable housing investments, aiming to improve health outcomes, expand care access and support long-term growth.
Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results. Q1 2026 saw ELV revenue up 1.5% to $49.5bn, adjusted EPS up 5.1% to $12.58, and a benefit expense ratio improvement to 86.8%. ELV raised 2026 adjusted EPS guidance to at least $26.75 and expects a return to 12% adjusted EPS growth in 2027.
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
Elevance Health beats Q1 EPS estimates as net investment income jumps 29.7%, offsetting membership decline and higher expenses.
Elevance Health, Inc. (ELV) Q1 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) came out with quarterly earnings of $12.58 per share, beating the Zacks Consensus Estimate of $10.68 per share. This compares to earnings of $11.97 per share a year ago.
Elevance Health Wednesday reported nearly $1.8 billion in first quarter net income as costs continued to be a drag on earnings of the nation's second-largest health insurance company.
Elevance Health raised its annual profit forecast on Wednesday, as it looks to keep medical costs in check.
Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.